By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


VBL Therapeutics 

6 Jonathan Netanyahu Street

Or Yehuda    60376  Israel
Phone: 97-236-346450 Fax: 97-236-346449



Company News
VBL Therapeutics (VBLX) Reports Topline Results From Phase 2 Studies Of VB-201 In Psoriasis And Ulcerative Colitis 2/17/2015 7:33:12 AM
VBL Therapeutics (VBLX) Announces Removal Of FDA Partial Clinical Hold On VB-111 2/17/2015 6:18:25 AM
VBL Therapeutics (VBLX) To Present Preclinical Data At Keystone Symposium On Liver Metabolism And Nonalcoholic Fatty Liver Disease 2/9/2015 7:42:44 AM
VBL Therapeutics (VBLX) Receives European Patent Issuance On Lecinoxoid Platform Technology 2/6/2015 7:35:16 AM
VBL Therapeutics (VBLX) Announces Ron Cohen And Philip Serlin Nominated To Board Of Directors 1/20/2015 7:38:17 AM
VBL Therapeutics (VBLX) Announces Positive Phase 2a Data For VB-111 In Recurrent Thyroid Cancer 12/22/2014 7:16:37 AM
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014 7:19:53 AM
VBL Therapeutics (VBLX) To Present Company Overview At Upcoming Conferences 11/25/2014 11:30:06 AM
VBL Therapeutics (VBLX) Announces Third Quarter 2014 Financial Results 11/13/2014 10:22:53 AM
VBL Therapeutics (VBLX) To Present Interim Phase 2 Data From VB-111 In Recurrent Glioblastoma At 19th Annual Scientific Meeting Of The Society For Neuro-Oncology (SNO) 11/13/2014 7:30:35 AM